Nebulized Beta Adrenergic Agonist Therapy for Lung Diseases

CMS does not make a national coverage determination for nebulized beta adrenergic agonist therapy for lung diseases; coverage, limitations, documentation, and frequency should be determined by local Medicare Administrative Contractors through local coverage determinations or case-by-case adjudication. There are no nationally listed covered or non-covered indications in this NCD. Providers should consult the applicable local MAC LCDs for clinical criteria, documentation, and authorization requirements.

"No national coverage determination is made for nebulized beta adrenergic agonist therapy; coverage decisions must be made by local Medicare Administrative Contractors via local coverage determinati..."

Sign up to see full coverage criteria, indications, and limitations.